- Target Sequencing (amplicon, gene panel)
- Small whole genome sequencing (bacteria, viruses)
- Profiling target gene expression
- Long Sequencing Amplicon
- Analysis and miRNAs and small RNAs
Illumina
Instrument
Illumina's smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.
– Average running time from 9–17.5 hours
– Maximum capacity of 1.2 Gb;
– Maximum number of reading passages per run: 4 million;
– Maximum reading length 2 × 150 bp
– Dimensions 42.5 cm × 30.5 cm × 33 cm (16.8 in × 12 in × 13 in)
Weight 15.9 kg (35 lb)
Read length | Total time | Output |
1 × 36 bp | 9 hours | 144 Mb |
1 × 50 bp | 9 hours | 200 Mb |
1 × 75 bp | 10 hours | 300 Mb |
2 × 75 bp | 13 hours | 600 Mb |
2 × 150 bp | 17.5 hours | 1.2 Gb |
Details: https://sapac.illumina.com/systems/sequencing-platforms/iseq.html
EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.
SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.
SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.
BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test
Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time
The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.
The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC
PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.
Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time
TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants